Lyell Immunopharma, Inc. Board of Directors

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Dr. Lynn Seely M.D., Ph.D.

Dr. Lynn Seely M.D., Ph.D.

President, CEO & Director

Dr. Crystal L. Mackall M.D.

Dr. Crystal L. Mackall M.D.

Founder & Scientific Advisor

Mr. Bryan Selby

Mr. Bryan Selby

Senior Vice President of Clinical Development Operations

Dr. Richard D. Klausner M.D.

Dr. Richard D. Klausner M.D.

Founder & Executive Chairman

Ms. Ellen Rose

Ms. Ellen Rose

Senior Vice President of Communications & Investor Relations

Nellie Dillery

Nellie Dillery

Director of Accounting

Mr. Charles W. Newton

Mr. Charles W. Newton

Chief Financial Officer

Ms. Ann Tomlin

Ms. Ann Tomlin

Senior Vice President of Human Resources

Mr. Matthew Lang J.D.

Mr. Matthew Lang J.D.

Chief Business Officer, Chief Legal Officer & Corporate Secretary

Prof. Stanley R. Riddell M.D.

Prof. Stanley R. Riddell M.D.

Founder & Scientific Advisor

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.